Wells Fargo Maintains Overweight on Kymera Therapeutics, Lowers Price Target to $35
Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and lowers the price target from $62 to $35.
Kymera Therapeutics Received FDA Orphan Drug Designation for Treatment of Peripheral T-cell Lymphoma
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=879422
Kymera Therapeutics Highlights Presented Preclinical Data On Co.’s KT-474 On Immune, Skin Cells At Society For Investigative Dermatology Meeting May 19
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, presented data demonstrating that the
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
81 Biggest Movers From Yesterday
Gainers
Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday.
Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Lowers Price Target to $35
Morgan Stanley analyst Vikram Purohit maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and lowers the price target from $66 to $35.
80 Biggest Movers From Yesterday
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume.
Mid-Afternoon Market Update: Kymera Therapeutics Drops After Q1 Results; Belite Bio Shares Spike Higher
U.S. stocks traded slightly higher toward the end of trading on Tuesday.